Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radiosensitization of hematopoietic precursor cells (CFU/sub c/) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR)

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
The potential use of bromodeoxyuridine (BUdR) as a radiosensitizer given by an intermittent intravenous route is being studied in a Phase I/II trial at the Naitonal Cancer Institute. In order to assess the extent of radiosensitization, we have studied the radiation response of human bone marrow cells CFUc taken form 6 patients prior to and after a 14-day infusion of BUdR. Varying concentrations (1000-1500 mg) of BUdR were infused for 12 hours 12 hours every 24 hours for up to 14 consecutive days. Cells survival was determined by colony formation of CFUc in soft agar suspensions. X ray survival curves were generated over a dose range of 0-300 rad and the slopes of the survival curves (D/sub 0/) before and after BUdR infusion were compared. Radiation enhancement ratios (ER)(D/sub 0/ per-BUdR/D/sub 0/ post-BUdR) ranged form 1.0-2.2 and appeared to be BUdR dose dependent. Above 650 mg/m/sub 2//12 hours is well tolerated and may result in radiosensitizaiton of CFUc in man.
Research Organization:
National Cancer Inst., Bethesda, MD
OSTI ID:
5514546
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 9:4; ISSN IOBPD
Country of Publication:
United States
Language:
English